Hims & Hers Raises Guidance, Wegovy Shipments Surge

What happened

Hims & Hers Health raised its FY2026 revenue guidance to $2.8-$3.0 billion despite reporting a Q1 EPS loss distorted by $28.5 million in inventory write-downs tied to its strategic shift toward branded GLP-1s. The company shipped over 125,000 Wegovy prescriptions in the first six weeks of its Novo Nordisk partnership, suggesting conversion rates are outperforming bearish expectations. Gross margin fell to 65% but adjusted gross margin exceeded 70% after excluding $33 million in restructuring charges, signaling underlying improvement. However, the company faces ongoing regulatory risks including an FDA statement naming Hims and an HHS referral to DOJ, along with a $15 million FTC accrual. The stock trades at ~$30, near the low end of the valuation range, but investors await visible proof that branded GLP-1 scaling can restore margins and mitigate legal overhangs.

Implication

The strong early Wegovy shipments provide initial validation of the branded GLP-1 transition thesis, reducing the risk of demand destruction from the compound exit. However, the thesis remains unconfirmed until Hims discloses branded mix KPIs and gross margin rebounds toward 70%+ in Q2. Legal risks (DOJ/FDA/FTC) could still cap upside or trigger sharp downside. Investors should wait for Q2 results (Aug 2026) before adding positions; any weakness below $22 offers a more attractive entry. The stock's elevated EV/EBITDA of 47x leaves little room for error, so patience is warranted until the re-assessment window delivers clearer data.

Thesis delta

The initial Wegovy shipment data suggests the branded transition may be scaling faster than feared, reducing bear-case probability of demand collapse. However, the thesis still requires Q2 margin improvement and legal clarity; the core thesis of 'wait for proof' remains intact, with a slightly improved risk/reward tilt.